Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 131

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 131
---
— (114,415)$30.52 Forfeited(37,550)$30.42 — $— (37,550)$30.42 Nonvested, June 30, 2025 (unaudited)419,216$30.56 20,000$28.63 439,216$30.47 

10.    Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2025 and 2024 (dollars in thousands, except share and per share amounts):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Numerator:Net earnings$22,499 $19,916 $10,672 $20,040 Denominator:Weighted average shares outstanding, basic56,024,771 54,978,781 55,945,434 54,890,265 Effect of dilutive securities:Stock options and stock awards618,418 745,502 743,320 785,209 Weighted average shares outstanding, diluted56,643,189 55,724,283 56,688,754 55,675,474 Earnings per share, basic$0.40 $0.36 $0.19 $0.37 Earnings per share, diluted$0.40 $0.36 $0.19 $0.36 The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted earnings per share, because their inclusion would be anti-dilutive:Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Stock options and stock awards588,422 971,683 836,462 799,798 

11.    Income Tax Expense (Benefit)

The following table provides information regarding the Company's income tax expense (benefit) for the three and six months ended June 30, 2025 and 2024 (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Income tax expense (benefit)$(5,830)$6,386 $166 $